Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. (AKBA) reports a corporate governance event dated December 14, 2022. The company is a biopharmaceutical entity incorporated in Delaware with principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of Violetta Cotreau, the Chief Accounting Officer, who notified the company of her resignation to pursue a new career opportunity. Her effective departure date is December 30, 2022.
Management Commentary and Personnel Actions
- Appointment: The Board of Directors appointed David A. Spellman, the Company's Chief Financial Officer, as the principal accounting officer effective December 30, 2022.
- Background: Mr. Spellman, age 46, joined Akebia in June 2020. He possesses two decades of experience in the biopharmaceutical and healthcare industries, including prior roles as CFO at Intarcia Therapeutics and Mersana Therapeutics, and extensive tenure at Vertex Pharmaceuticals.
- Transition: Ms. Cotreau is expected to continue in her current role until the effective date to ensure a smooth transition.
Investor Verification Checklist
- Confirm the effective date of the Chief Accounting Officer transition (December 30, 2022).
- Verify the qualifications and tenure of the new principal accounting officer, David A. Spellman.
- Review subsequent filings for any impact on internal controls or financial reporting timelines due to this leadership change.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.